Stocks · News reference
Rhythm Pharmaceuticals Q3 2026 Earnings Call Transcript
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AstraZeneca Proposes $10 Billion Acquisition of Rhythm Pharmaceuticals
AstraZeneca has reportedly made a non-binding offer to acquire Rhythm Pharmaceuticals for approximately $10 billion, or up to $134 per share.
AstraZeneca Makes $10 Billion Takeover Offer for Rhythm Pharmaceuticals
AstraZeneca has reportedly submitted a $10 billion acquisition offer for Rhythm Pharmaceuticals at $124 per share.
Rhythm Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 21.67%
'AstraZeneca Made $10 Billion Offer For Rhythm Pharmaceuticals; Rhythm Specializes In Treatments For Metabolic Conditions And Severe Obesity' - WSJ Exclusive
NICE Issues Positive Guidance for IMCIVREE in Adults with Bardet-Biedl Syndrome
The National Institute for Health and Care Excellence (NICE) has updated its guidance to include adults living with genetically confirmed Bardet-Biedl syndrome (BBS) for IMCIVREE treatment.